Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly i···【more】
Release date：2024-08-23Recommended：302
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib ···【more】
Release date：2024-08-23Recommended：237
As a PIK3CA inhibitor, Alpelisib works synergistically with fulvestrant to signi···【more】
Release date：2024-08-23Recommended：318
Alpelisib effectively inhibits the proliferation of HR/HER2- breast cancer cells···【more】
Release date：2024-08-23Recommended：331
The combination of Alpelisib and fulvestrant specifically targeted patients with···【more】
Release date：2024-08-23Recommended：294
Koselugois a multifunctional targeted therapy drug, which can be used as a small···【more】
Release date：2024-08-23Recommended：289
Koselugo is a targeted therapy that targets specific cancers by inhibiting the a···【more】
Release date：2024-08-23Recommended：326
Koselugo is a targeted therapy drug for the treatment of low-grade serous ovaria···【more】
Release date：2024-08-23Recommended：332
Koselugois an anti-cancer drug targeting MEK protein, which can successfully blo···【more】
Release date：2024-08-23Recommended：284
Koselugo is an MEK protein-targeted anticancer agent that can effectively cut th···【more】
Release date：2024-08-23Recommended：301
Koselugo is an anti-cancer drug targeting MEK protein, which inhibits tumor cell···【more】
Release date：2024-08-23Recommended：384
By targeting and inhibiting the activity of MEK protein, Koselugo effectively cu···【more】
Release date：2024-08-23Recommended：331
